NO20072667L - Preparation Process - Google Patents
Preparation ProcessInfo
- Publication number
- NO20072667L NO20072667L NO20072667A NO20072667A NO20072667L NO 20072667 L NO20072667 L NO 20072667L NO 20072667 A NO20072667 A NO 20072667A NO 20072667 A NO20072667 A NO 20072667A NO 20072667 L NO20072667 L NO 20072667L
- Authority
- NO
- Norway
- Prior art keywords
- preparation process
- compounds
- preparation
- her1
- her4
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for fremstilling av forbindelser med formel (IV) eller et farmasøytisk akseptabelt salt derav. Forbindelsene som er fremstilt ved fremgangsmåten ifølge oppfinnelsen, inhiberer tyrosinkinase-aktiviteten til vekstfaktor-reseptorer så som HER1, HER2 og HER4, og dette gjør dem anvendelige som antiproliferative midler for behandling av kreft og andre sykdommer.The present invention provides a process for the preparation of compounds of formula (IV) or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit the tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4, making them useful as antiproliferative agents for the treatment of cancer and other diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63833504P | 2004-12-22 | 2004-12-22 | |
| PCT/US2005/047630 WO2006069395A2 (en) | 2004-12-22 | 2005-12-21 | Synthetic process for the preparation of biocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072667L true NO20072667L (en) | 2007-09-06 |
Family
ID=36177994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072667A NO20072667L (en) | 2004-12-22 | 2007-05-25 | Preparation Process |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060155125A1 (en) |
| EP (1) | EP1896475A2 (en) |
| JP (1) | JP2008525503A (en) |
| CN (1) | CN101087792A (en) |
| AR (1) | AR052276A1 (en) |
| NO (1) | NO20072667L (en) |
| PE (1) | PE20060951A1 (en) |
| TW (1) | TW200635927A (en) |
| WO (1) | WO2006069395A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7358256B2 (en) * | 2005-03-28 | 2008-04-15 | Bristol-Myers Squibb Company | ATP competitive kinase inhibitors |
| EP2376491B1 (en) | 2008-12-19 | 2015-03-04 | Cephalon, Inc. | Pyrrolotriazines as alk and jak2 inhibitors |
| UY34484A (en) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| CN103450204B (en) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | Pyrroles [2,1-f] [1,2,4] triazin compound, Preparation Method And The Use |
| US20240132521A1 (en) | 2022-08-22 | 2024-04-25 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| JP2005529890A (en) * | 2002-04-23 | 2005-10-06 | ブリストル−マイヤーズ スクイブ カンパニー | Aryl ketone pyrrolotriazine compounds useful as kinase inhibitors |
| US7102001B2 (en) * | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| US7064203B2 (en) * | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7102003B2 (en) * | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
-
2005
- 2005-12-16 TW TW094144843A patent/TW200635927A/en unknown
- 2005-12-21 JP JP2007548614A patent/JP2008525503A/en not_active Withdrawn
- 2005-12-21 CN CNA2005800442330A patent/CN101087792A/en active Pending
- 2005-12-21 EP EP05856095A patent/EP1896475A2/en not_active Withdrawn
- 2005-12-21 WO PCT/US2005/047630 patent/WO2006069395A2/en not_active Ceased
- 2005-12-21 US US11/314,794 patent/US20060155125A1/en not_active Abandoned
- 2005-12-22 AR ARP050105516A patent/AR052276A1/en unknown
-
2006
- 2006-01-03 PE PE2006000001A patent/PE20060951A1/en not_active Application Discontinuation
-
2007
- 2007-05-25 NO NO20072667A patent/NO20072667L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008525503A (en) | 2008-07-17 |
| AR052276A1 (en) | 2007-03-07 |
| US20060155125A1 (en) | 2006-07-13 |
| CN101087792A (en) | 2007-12-12 |
| WO2006069395A3 (en) | 2006-10-19 |
| EP1896475A2 (en) | 2008-03-12 |
| PE20060951A1 (en) | 2006-09-14 |
| TW200635927A (en) | 2006-10-16 |
| WO2006069395A2 (en) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20062763L (en) | Pyrrolotriazine Compounds as Kinase Inhibitors | |
| WO2004054514A3 (en) | C-6 modified indazolylpyrrolotriazines | |
| MXPA04004492A (en) | C-5 modified indazolylpyrrolotriazines. | |
| NO20061743L (en) | quinazoline | |
| NO20072747L (en) | Process for the preparation of indazole compounds | |
| NO20070681L (en) | 2, 4, 6-Trisubstituted pyrimidines as phosphotidylinositol (PI) -3-kinase inhibitors and their use in the treatment of cancer | |
| WO2005065266A8 (en) | Di-substituted pyrrolotriazine compounds | |
| NO20090581L (en) | Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors | |
| NO20070656L (en) | 2,4,6-Trisubstituted pyrimidines as phosphotidylinositol (PI) -3-kinase inhibitors and their use in the treatment of cancer | |
| NO20070199L (en) | Substituted quinazolones as anti-cancer agents | |
| NO20066081L (en) | Quinazoline derivatives as erbB receptor tyrosine kinases | |
| NO20070655L (en) | 2,4,6-Trisubstituted pyrimidines as phosphotidylinositol (PI) -3-kinase inhibitors and their use in the treatment of cancer | |
| NO20090580L (en) | Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors | |
| EA200970611A1 (en) | SUBSTITUTED PYRAZOLOHINAZYLINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS KINASE INHIBITORS | |
| NO20090631L (en) | Morpholine pyrimidine derivatives useful in the treatment of proliferative disorders | |
| GB0112348D0 (en) | Compounds | |
| NO20081454L (en) | Met kinase inhibitors | |
| MXPA04004107A (en) | Quinazoline derivatives for the treatment of abnormal cell growth. | |
| NO20084496L (en) | Pyridyl and pyrimidinyl substituted pyrrole, thiophene and furan derivatives as kinase inhibitors | |
| TN2012000062A1 (en) | Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer | |
| WO2009007751A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| NO20061327L (en) | quinazoline | |
| EA200801287A1 (en) | Pyrimidine derivatives for the treatment of anomalous cell growth | |
| EP1973407A4 (en) | Spiro compounds and methods of use | |
| AU2009282962A8 (en) | Compounds as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |